Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712379 | 0.90 | AKR1C3 (0.51) | AKR1C3AKR1C2ACHEPDE3BPDE3A | |
| SCHEMBL16582524 | 0.85 | AKR1C3 (0.49) | AKR1C3AKR1C2ACHEPDE3BPDE3A | |
| SCHEMBL8265084 | 0.85 | ACHE (0.54) | AKR1C3AKR1C2ACHEPDE3BPDE3A | |
| SCHEMBL15344231 | 0.85 | ACHE (0.54) | AKR1C3AKR1C2ACHEPDE3BPDE3A | |
| SCHEMBL14926547 | 0.84 | CNR1 (0.49) | PDE3BPDE3ACNR1MEN1KMT2A | |
| SCHEMBL15495645 | 0.82 | CNR1 (0.48) | AKR1C3AKR1C2PDE3BPDE3ACNR1 | |
| SCHEMBL24329717 | 0.81 | ACHE (0.50) | AKR1C3AKR1C2ACHEPDE3BPDE3A | |
| SCHEMBL10094674 | 0.81 | ACHE (0.54) | AKR1C3AKR1C2ACHERPS6KA3NPC1 | |
| SCHEMBL3641153 | 0.80 | MAPK14 (0.50) | AKR1C3AKR1C2ACHEPDE3BPDE3A | |
| SCHEMBL22421796 | 0.79 | AKR1C3 (0.50) | AKR1C3AKR1C2PDE3BPDE3ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-9827229-B2 | Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections | INVENIO THERAPEUTICS INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20120025177-A1 | Phosphorescent light-emitting iridium complex containing pyridyltriazole ligand | SOLVAY SA (BE) | 2012-02-02 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2349990-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | Pimco 2664 Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010032010-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032010-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120025177-A1 | Phosphorescent light-emitting iridium complex containing pyridyltriazole ligand | PPIP5K2, HPRT1, PHPT1 | AKR1C3 3856/4885AKR1C2 4199/4885ACHE 2347/4885 |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | SOST, PSAP, ARSA | AKR1C3 1979/4885AKR1C2 2332/4885ACHE 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.